by Raynovich Rod | Oct 25, 2020 | 2009-2017 Life Science Portfolios, 2020 Rayno Biopharmaceuticals Portfolio, Macro
Update-1 10/26…S&P takes a 1.86% Hit on Lack of Stimulus and a Spike in Cases First look at winners among our holdings: ABT up 1.13% post last week’s earnings, AZN up 2.06% on resumed vaccine trials, BDX up 0.72%, OSUR up 6.77% a rapid COVID test...
by Raynovich Rod | Jul 9, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro, Vaccines
Update-4 7/15 1:30P…Volatlity hits COVID vaccine players; BNTX, INO, NVAX down, MRNA up. Comment from CNBC contributor: “maybe vaccine news is priced in”, shows how hard it is to play daily news flow on coronavirus vaccine stocks. Strong Coronavirus...
by Raynovich Rod | Mar 8, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
3/30 11;30a Major news on COVID-19 diagnostics spark rally. Abbott launches 5 minute test. ABT up 7.28% ,JNJ up 6.8%, all large caps up, IBB up 2.55, XBI up 1.61%. Risk reward still looks good for biotech by year-end 2020. See IBB 2 yr chart below. ======== 3/27 After...
by Raynovich Rod | Feb 22, 2020 | Biopharmaceuticals, Macro
2/28 10:15a XBI down to $86 level. Looking today to see what to buy. Bought VCYT yesterday at $23+ GNMK up 39% to $5 handle. Diagnostic and tools sector could be the place to look for buys but stocks are extremely volatile—-but now one hour later up only 20%!!...
by Raynovich Rod | Jan 31, 2020 | Biopharmaceuticals, Macro
Update-1 2/3…3:30p EST… Biopharma stocks firm up after a bad week Large caps are strong with Gilead Sciences (GILD) up over 5% on a story about an experimental antiviral therapy for coronavirus China. GILD is one of the leading antiviral companies for...
by Raynovich Rod | Jan 6, 2020 | Biopharmaceuticals, Macro
Update-1 1/9/20 “Sigh of Relief” rally for second day -Don’t Fight the FED Dont confuse a momentum rally with fundamental analysis as we are at new highs with market PEs>18. Large cap biiopharmas are at new highs Mid-cap 2%+ winners today: ACAD,...
by Raynovich Rod | Dec 9, 2019 | Biopharmaceuticals, Macro
Update-1 …12/12/19…China Deal Announcement Boosts Dow S&P and NASDAQ. IBB up 0.68%, XBI up 0.58%, XLV up 0.93%. Large cap leaders: ABBV ALXN BMY, Chips, energy, financials strong; real estate weak. 10 year yield moves up to 1.894% =========== Early...
by Raynovich Rod | Nov 10, 2019 | Biopharmaceuticals, Macro
Biotech and Healthcare Stocks Notch -Up with Bullish Tape Action Since we called the early October reversal for healthcare and biotech stocks we have seen great gains of 5-7% with more gains ahead assuming good clinical news and M&A. Friday we saw a good tape...
by Raynovich Rod | Nov 7, 2019 | Biopharmaceuticals, Macro
Biotech Action Today is Muddled-Midday Selloff presumably on “Recycling” of China Trade Chatter Uncertainty Remains on Trade War and Tariffs Little rally in gene therapy stocks; 1% + Winners include QURE RGNX SRPT; XBI up only 0.26% as rally faded. Mixed...
by Raynovich Rod | Oct 15, 2019 | Biopharmaceuticals, Macro
Update-1 Large caps were mixed but our top picks are doing well: ABBV,BMY,MRK,RHHBY. But bad news from JNJ and BA may have curbed buyer’s sentiment. United Health (UNH) off Mondays lows of $220 to $245. In summary it looks like a good time fo adding larger cap...
